MX9305621A - (s)-(+)-hidroxicloroquina. - Google Patents

(s)-(+)-hidroxicloroquina.

Info

Publication number
MX9305621A
MX9305621A MX9305621A MX9305621A MX9305621A MX 9305621 A MX9305621 A MX 9305621A MX 9305621 A MX9305621 A MX 9305621A MX 9305621 A MX9305621 A MX 9305621A MX 9305621 A MX9305621 A MX 9305621A
Authority
MX
Mexico
Prior art keywords
hydroxychloroquine
treatment
malaria
medicament
diseases
Prior art date
Application number
MX9305621A
Other languages
English (en)
Inventor
Vera Johanna Stecher
William Francis Michne
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of MX9305621A publication Critical patent/MX9305621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención provee (S)-(+)-hidroxicloroquina substancialmente libre de (R)-(-)-hidroxicloroquina o una sal de adición ácida farmacéuticamente aceptable, el uso en la fabricación de un medicamento para el tratamiento de malaria, lupus eritematosos o artritis reumatoide y una composición que la contiene para el tratamiento de esas enfermedades.
MX9305621A 1992-09-15 1993-09-13 (s)-(+)-hidroxicloroquina. MX9305621A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/945,032 US5314894A (en) 1992-09-15 1992-09-15 (S)-(+)-hydroxychloroquine

Publications (1)

Publication Number Publication Date
MX9305621A true MX9305621A (es) 1994-03-31

Family

ID=25482508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305621A MX9305621A (es) 1992-09-15 1993-09-13 (s)-(+)-hidroxicloroquina.

Country Status (18)

Country Link
US (1) US5314894A (es)
EP (1) EP0588430B1 (es)
JP (1) JPH06199801A (es)
KR (1) KR940007002A (es)
AT (1) ATE166646T1 (es)
AU (2) AU4732693A (es)
CA (1) CA2104903A1 (es)
CZ (1) CZ192393A3 (es)
DE (1) DE69318783D1 (es)
FI (1) FI934051A (es)
HU (1) HUT70025A (es)
IL (1) IL107004A0 (es)
MX (1) MX9305621A (es)
MY (1) MY109822A (es)
NO (1) NO180677C (es)
NZ (1) NZ248671A (es)
PH (1) PH30153A (es)
SK (1) SK98793A3 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US20020198231A1 (en) * 1999-07-13 2002-12-26 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2005062723A2 (en) * 2003-11-24 2005-07-14 Ipca Laboratories Limited An improved process for the preparation of 7-chloro-4-(5-n-ehtyl-n-2-hydroxyethylamine)-2-pentyl] aminoquinoline and its intermediates
KR101115412B1 (ko) 2008-09-08 2012-06-12 주식회사 대희화학 하이드록시클로로퀸의 신규 제조방법
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
CN103096891A (zh) 2010-06-24 2013-05-08 判米德有限公司 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN105693605B (zh) * 2016-03-09 2017-12-22 西安科技大学 一种光学纯(r)/(s)‑氯喹的不对称合成方法
CN105693606B (zh) * 2016-03-09 2017-12-05 西安科技大学 一种光学纯(r)/(s)‑羟氯喹的不对称合成方法
CN110283121A (zh) * 2019-08-06 2019-09-27 华东理工大学 羟氯喹的合成方法
CN113350344A (zh) * 2020-03-06 2021-09-07 华南理工大学 左旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN113350343A (zh) * 2020-03-06 2021-09-07 华南理工大学 右旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN115397402A (zh) * 2020-04-14 2022-11-25 格兰尼斯制药公司 包含羟氯喹和/或氯喹的经皮和/或局部递送***
WO2021214544A1 (en) * 2020-04-20 2021-10-28 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine
US11578041B2 (en) * 2020-04-21 2023-02-14 Genovate Biotechnology Co. Ltd. Crystals of hydroxychloroquine sulfate
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
EP3915562A1 (en) 2020-05-31 2021-12-01 Genovate Biotechnology Co., Ltd. Treatment of lupus erythematosus using s- hydroxychloroquine
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111803501B (zh) * 2020-06-17 2022-10-18 南方科技大学 手性氯喹羟氯喹作为降低心脏毒性的用途
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112505198A (zh) * 2020-12-29 2021-03-16 珠海润都制药股份有限公司 一种s-硫酸羟氯喹异构体检验方法
JP2024520741A (ja) * 2021-06-04 2024-05-24 ジェノベート バイオテクノロジー カンパニー リミテッド Ｓ－ヒドロキシクロロキンを用いた抗リン脂質症候群の処置
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN115089584A (zh) * 2022-06-14 2022-09-23 广州惠善医疗技术有限公司 手性羟氯喹或其药学上可接受的盐在制备防诊治免疫疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) * 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives

Also Published As

Publication number Publication date
PH30153A (en) 1997-01-21
IL107004A0 (en) 1993-12-28
CZ192393A3 (en) 1994-03-16
NO933293L (no) 1994-03-16
NO180677C (no) 1997-05-28
EP0588430B1 (en) 1998-05-27
DE69318783D1 (de) 1998-07-02
SK98793A3 (en) 1994-09-07
MY109822A (en) 1997-08-30
HUT70025A (en) 1995-09-28
ATE166646T1 (de) 1998-06-15
CA2104903A1 (en) 1994-03-16
FI934051A (fi) 1994-03-16
HU9302613D0 (en) 1993-12-28
NZ248671A (en) 1995-04-27
AU7549496A (en) 1997-04-10
FI934051A0 (fi) 1993-09-15
NO933293D0 (no) 1993-09-15
JPH06199801A (ja) 1994-07-19
US5314894A (en) 1994-05-24
AU4732693A (en) 1994-03-24
NO180677B (no) 1997-02-17
EP0588430A1 (en) 1994-03-23
KR940007002A (ko) 1994-04-26

Similar Documents

Publication Publication Date Title
FI934051A (fi) (S)-(+)-hydroxiklorokin
IL98810A0 (en) Pharmaceutical compositions containing flupirtine for combating muscular tension disorders and their preparation
GB8712073D0 (en) Medicament
HU0301425D0 (en) K-252a-derivatives and pharmaceutical composition containing thereof
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
IL111239A0 (en) Substituted 1-naphthyl-3-pyrazolecarboxamides, their preparation and pharmaceutical compositions containing them
FI924744A0 (fi) Terapeutiska aemnen
IT9041529A0 (it) Dispositivo per la correzione chirurgica dell'ametropia
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
GB8912303D0 (en) Therapeutic agents
IL99077A0 (en) New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
EP0735897A4 (en) ALLERGY PROPHYLAXIS
IT1252659B (it) Procedimento per la depurazione dell'1,1,1-trifluoro-2-fluoroetano e dell'1,1,1-trifluoro-2,2-dicloroetano
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina
RU93052163A (ru) (s) - (+) - гидроксихлорохин и композиция для лечения
ZA961897B (en) 6,7-substituted-2-aminotetralines and use thereof
ITMI912019A1 (it) Analoghi dell'irudina e procedimento per la loro preparazione
DK0610076T3 (da) Cytotoksiske forbindelser
AU6955294A (en) Agents for the prevention and treatment of parkinson's disease
RU1833738C (ru) Cпocoб лeчehия cиhдpoma чapлиha
ITFI930001A1 (it) Medicamento per il trattamento dell'asma.
IT225039Z2 (it) Manipolo per sollecitazioni elettrostatiche dell'epidermide
IT8719390A0 (it) Composizione farmaceutica per la prevenzione e il trattamento dell'aterosclerosi.
IT8822114A0 (it) Composti utili per il trattamento terapeutico dell'artrite reumatoide

Legal Events

Date Code Title Description
FA Abandonment or withdrawal